These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 20839307)
21. The need for regulatable vectors for gene therapy for Parkinson's disease. Cress DE Exp Neurol; 2008 Jan; 209(1):30-3. PubMed ID: 17942096 [TBL] [Abstract][Full Text] [Related]
22. The scientific and clinical basis for the treatment of Parkinson disease (2009). Olanow CW; Stern MB; Sethi K Neurology; 2009 May; 72(21 Suppl 4):S1-136. PubMed ID: 19470958 [TBL] [Abstract][Full Text] [Related]
27. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit. Carroll WM Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446 [TBL] [Abstract][Full Text] [Related]
28. Treatments for Parkinson disease--past achievements and current clinical needs. Poewe W Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317 [TBL] [Abstract][Full Text] [Related]
29. An update on the treatment of Parkinson's disease. Jankovic J Mt Sinai J Med; 2006 Jul; 73(4):682-9. PubMed ID: 16878274 [TBL] [Abstract][Full Text] [Related]
30. Current management of Parkinson's disease. Salawu F; Olokoba A; Danburam A Ann Afr Med; 2010; 9(2):55-61. PubMed ID: 20587924 [TBL] [Abstract][Full Text] [Related]
31. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Stocchi F Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296 [TBL] [Abstract][Full Text] [Related]
32. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. Chen JJ Am J Manag Care; 2010 Mar; 16 Suppl Implications():S87-93. PubMed ID: 20297871 [TBL] [Abstract][Full Text] [Related]
33. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Bonuccelli U; Del Dotto P; Rascol O Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557 [TBL] [Abstract][Full Text] [Related]
34. Recognition and management of Parkinson's disease during the premotor (prodromal) phase. Truong DD; Wolters EC Expert Rev Neurother; 2009 Jun; 9(6):847-57. PubMed ID: 19496688 [TBL] [Abstract][Full Text] [Related]
38. Parkinson's disease: 10 years of progress, 1997-2007. Fahn S Mov Disord; 2010; 25 Suppl 1():S2-14. PubMed ID: 20187239 [TBL] [Abstract][Full Text] [Related]
39. Advances in the pharmacologic management of early Parkinson disease. Hauser RA; Zesiewicz TA Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756 [TBL] [Abstract][Full Text] [Related]
40. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Schapira AH; Albrecht S; Barone P; Comella CL; McDermott MP; Mizuno Y; Poewe W; Rascol O; Marek K Mov Disord; 2010 Aug; 25(11):1627-32. PubMed ID: 20544810 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]